GEO series
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
GSE275152
Homo sapiens (human)
RNA-seq (gene expression)
42 samples
Submitted 2024/08/19
Platform GPL24676
At a glance
RNA-seq (gene expression) · human · 42 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 42 samples: 42 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potencyNature communications · 2024
Summary (written by the submitters)
The intensive nutrient requirements needed to sustain T cell activation and proliferation combined with competition for nutrients within the tumor microenvironment raise the prospect that glucose availability may limit CAR T cell function. Here, we sought to test the hypothesis that stable overexpression (OE) of the glucose transporter GLUT1 in primary human CAR-T cells would improve their function and antitumor potency.
Read the full summary ↓
We observed that GLUT1OE in CAR-T cells increased glucose consumption, glycolysis, glycolytic reserve and oxidative phosphorylation and these effects were associated with decreased T cell exhaustion and increased Th17 differentiation. GLUT1OE also induced broad metabolic reprogramming associated with increased glutathione41 mediated resistance to reactive oxygen species, and increased inosine accumulation. When challenged with tumors, GLUT1OE CAR-T cells secreted more proinflammatory cytokines and mediated enhanced cytotoxicity in vitro and demonstrated superior tumor control and persistence in vivo. Our collective findings support a model wherein glucose availability is rate limiting for optimal effector CAR-T cell function and demonstrate that enhancing glucose availability via GLUT1OE provides a new approach to augment antitumor immune function.
Published in
Guerrero JA, Klysz DD, Chen Y et al.
· Nature communications 2024
· PMID 39370422
· doi:10.1038/s41467-024-52666-y
This dataset
Download · which file do I need?
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
1 · Just have a look
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
2 · Re-analyse it
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE275152_RAW.tar (it can run to tens of gigabytes).
3 · Start from the raw reads
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1148127 and SRA study SRP526702. Searching any of these in the dataset finder brings you back here.
Study design
42 samples, each with a distinct title — no replicated groups
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 42 sample titles: 42 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
Samples in this study
- GSM8472097 RNA-seq of CD19-CAR T cells from healthy human donor 11, unstimulated
- GSM8472098 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 11, unstimulated
- GSM8472099 RNA-seq of CD19-CAR T cells from healthy human donor 16, unstimulated
- GSM8472100 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 16, unstimulated
- GSM8472101 RNA-seq of CD19-CAR T cells from healthy human donor 17, unstimulated
- GSM8472102 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 17, unstimulated
- GSM8472103 RNA-seq of HA-CAR T cells from healthy human donor 77, unstimulated
- GSM8472104 RNA-seq of HA-CAR T cells from healthy human donor 86, unstimulated
- GSM8472105 RNA-seq of HA-CAR T cells from healthy human donor 90, unstimulated
- GSM8472106 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 77, unstimulated
- GSM8472107 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 86, unstimulated
- GSM8472108 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 90, unstimulated
- GSM8472109 RNA-seq of T cells from healthy human donor 61, 4h post-stimulation
- GSM8472110 RNA-seq of CD19-CAR T cells from healthy human donor 61, 4h post-stimulation
- GSM8472111 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 61, 4h post-stimulation
- GSM8472112 RNA-seq of HA-CAR T cells from healthy human donor 61, 4h post-stimulation
- GSM8472113 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 61, 4h post-stimulation
- GSM8472114 RNA-seq of T cells from healthy human donor 62, 4h post-stimulation
- GSM8472115 RNA-seq of CD19-CAR T cells from healthy human donor 62, 4h post-stimulation
- GSM8472116 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 62, 4h post-stimulation
- GSM8472117 RNA-seq of HA-CAR T cells from healthy human donor 62, 4h post-stimulation
- GSM8472118 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 62, 4h post-stimulation
- GSM8472119 RNA-seq of T cells from healthy human donor 63, 4h post-stimulation
- GSM8472120 RNA-seq of CD19-CAR T cells from healthy human donor 63, 4h post-stimulation
- GSM8472121 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 63, 4h post-stimulation
- GSM8472122 RNA-seq of HA-CAR T cells from healthy human donor 63, 4h post-stimulation
- GSM8472123 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 63, 4h post-stimulation
- GSM8472124 RNA-seq of T cells from healthy human donor 61, 14h post-stimulation
- GSM8472125 RNA-seq of CD19-CAR T cells from healthy human donor 61, 14h post-stimulation
- GSM8472126 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 61, 14h post-stimulation
- GSM8472127 RNA-seq of HA-CAR T cells from healthy human donor 61, 14h post-stimulation
- GSM8472128 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 61, 14h post-stimulation
- GSM8472129 RNA-seq of T cells from healthy human donor 62, 14h post-stimulation
- GSM8472130 RNA-seq of CD19-CAR T cells from healthy human donor 62, 14h post-stimulation
- GSM8472131 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 62, 14h post-stimulation
- GSM8472132 RNA-seq of HA-CAR T cells from healthy human donor 62, 14h post-stimulation
- GSM8472133 RNA-seq of GLUT1-OE HA-CAR T cells from healthy human donor 62, 14h post-stimulation
- GSM8472134 RNA-seq of T cells from healthy human donor 63, 14h post-stimulation
- GSM8472135 RNA-seq of CD19-CAR T cells from healthy human donor 63, 14h post-stimulation
- GSM8472136 RNA-seq of GLUT1-OE CD19-CAR T cells from healthy human donor 63, 14h post-stimulation
+ 2 more — browse all 42 samples with per-sample file links →
Datasets on a similar topic
- GSE277818 Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies 12 samples shares car-t, enhances
- GSE328224 Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory 11 samples shares car-t, reprogramming
- GSE286057 Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming 36 samples shares reprogramming, induces
- GSE282387 Temozolomide Induces Glioblastoma Dedifferentiation into Highly Malignant Stem-like Cells Through Senescence-Associated Reprogramming via HIF1α/HIF2α Regulation [RNA-seq] 12 samples shares reprogramming, induces
- GSE280564 Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype 12 samples shares reprogramming, induces
- GSE245149 NSD2 Overexpression in Myeloma Enhances Dependency on Mitochondrial High Energy Phosphate Transport Facilitated by Adenylate Kinase 2 [AS_RS] 12 samples shares overexpression, enhances
- GSE320375 On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy whereas preventing toxicity in glioblastoma 16 samples shares car-t
- GSE287613 p53 safeguards chemical reprogramming of human somatic cells towards pluripotency. 63 samples shares reprogramming, potency
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.